Superworth

Bristol-Myers Squibb price to book ratio BMY

Market value divided by the book value of the company's net assets, since 2009.

Today, Oct 23, 2026
5.6×
10-year median
5.3×
Against its 10-year history
59th
percentile: 0 is its lowest day, 100 its highest
10-year range
2.1× to 9.6×
Peer median
8.0×

Bristol-Myers Squibb's price to book ratio is 5.6× as of Oct 23, 2026.

That is above its ten-year median of 5.3×, close to the middle of its last ten years.

Over that time it ranged from 2.1× in Mar 2020 to 9.6× in Feb 2018.

The median for 9 large drugmakers of a similar size is 8.0×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far5.6×5.4×6.9×
20256.0×5.1×7.6×
20246.8×3.3×7.0×
20233.6×3.5×4.8×
20224.7×3.7×5.3×
20213.7×2.7×4.2×
20202.8×2.1×6.2×
20195.9×4.6×6.2×
20186.1×6.0×9.6×
20176.8×5.1×7.3×
20166.3×5.5×8.8×
20157.6×6.3×7.6×
20146.5×5.0×6.7×
20135.9×4.0×6.0×
20123.8×3.3×4.0×
20113.6×2.7×3.6×
20102.8×2.5×3.4×
20093.4×3.0×3.5×

Against its peers

Companies in Drug Manufacturers - General nearest Bristol-Myers Squibb's size, closest first, today.

CompanyPrice to book ratio
BMYBristol-Myers Squibb5.6×
PFEPfizer2.0×
GILDGilead Sciences16.4×
AMGNAmgen20.3×
MRKMerck8.5×
BIIBBiogen2.0×
ABBVAbbVien/m
JNJJohnson & Johnson7.5×
JAZZJazz Pharmaceuticals2.9×
LLYEli Lilly and35.4×
Peer median8.0×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Bristol-Myers Squibb

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.